Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Doxorubicin HCl (formerly known as Adriamycin; FI 106; Adriblastina; DOXOCELL; Doxolem; NSC-123127 etc.) is an anthracycline antibiotic agent with anticancer activity. It causes DNA damage and apoptosis in tumor cells and inhibits DNA topoisomerase II. The use of it as an antineoplastic agent was authorized. Doxorubicin, the hydroxylated congener of daunorubicin, is isolated from Streptomyces peucetius var. caesius. By intercalating between base pairs in the DNA helix, doxorubicin inhibits the synthesis of proteins by preventing DNA replication. Furthermore, topoisomerase II is inhibited by doxorubicin.
Targets |
Topoisomerase I ( IC50 = 0.8 μM ); Topoisomerase II ( IC50 = 2.67 μM ); Daunorubicins/Doxorubicins; HIV-1
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
Doxorubicin at varying concentrations was applied to parental ID8 or erastin-resistant ID8 cells for a duration of 24 hours.
|
||
Animal Protocol |
|
||
References |
[1]. Cancer Res . 2009 May 15;69(10):4294-300. [2]. Food Chem Toxicol . 2010 Jun;48(6):1425-38. [3]. Biochem J . 2011 Dec 1;440(2):175-83. [4]. Br J Cancer . 2011 Mar 15;104(6):957-67. [5]. J Biol Chem . 2012 Jun 29;287(27):22838-53. [6]. J Biol Chem . 2012 Mar 9;287(11):8001-12. [1]. Clin Cancer Res . 2012 May 1;18(9):2638-47. [2]. FEBS J . 2012 Jun;279(12):2182-91. [3]. Nat Rev Cancer . 2009 May;9(5):338-50. |
Molecular Formula |
C27H29NO11.HCL
|
|
---|---|---|
Molecular Weight |
579.98
|
|
Exact Mass |
579.15
|
|
Elemental Analysis |
C, 55.91; H, 5.21; Cl, 6.11; N, 2.42; O, 30.34
|
|
CAS # |
25316-40-9
|
|
Appearance |
Red solid powder
|
|
SMILES |
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl
|
|
InChi Key |
MWWSFMDVAYGXBV-RUELKSSGSA-N
|
|
InChi Code |
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1
|
|
Chemical Name |
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7242 mL | 8.6210 mL | 17.2420 mL | |
5 mM | 0.3448 mL | 1.7242 mL | 3.4484 mL | |
10 mM | 0.1724 mL | 0.8621 mL | 1.7242 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03712956 | Active Recruiting |
Drug: Caelyx® | Breast Cancer | European Institute of Oncology | March 25, 2016 | Phase 2 |
NCT04032964 | Active Recruiting |
Drug: Doxorubicin Drug: L19TNF |
Soft Tissue Sarcoma | Philogen S.p.A. | September 5, 2019 | Phase 1 |
NCT01746238 | Active Recruiting |
Drug: Doxorubicin Drug: Bevacizumab |
Sarcoma | Massachusetts General Hospital | March 2013 | Phase 1 |
NCT01840592 | Active Recruiting |
Drug: Sorafenib Drug: Doxorubicin |
Hepatocellular Carcinoma | Memorial Sloan Kettering Cancer Center |
April 2013 | Phase 2 |
NCT02451943 | Active Recruiting |
Drug: Doxorubicin Drug: Placebo |
Soft Tissue Sarcoma | Eli Lilly and Company | September 14, 2015 | Phase 3 |